Urological surgery and equipment

2019 ◽  
pp. 731-826
Author(s):  
John Reynard ◽  
Simon F Brewster ◽  
Suzanne Biers ◽  
Naomi Laura Neal
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Preoperative Preparation ◽  
Fourth Edition ◽  
Urological Surgery ◽  
Urological Procedures

This chapter covers the principles of urological surgery and the equipment commonly used in urological procedures. This includes preoperative preparation, including the management of patients on anticoagulants, and the fourth edition includes novel oral anticoagulants. Technology such as catheters, lasers, stents, telescopes, and diathermy are all discussed in detail and at a level suitable for the FRCS(Urol) examinations. The principles of consent and the recent Montgomery ruling are included in the fourth edition. The surgical principles of a range of urological operations are outlined, ranging from inguinoscrotal procedures to pelvic oncology procedures, including reconstruction.

scholarly journals MP06-15 POST OPERATIVE BLEEDING AND THOMBOTIC RISK FOR PATIENTS ON NOVEL ORAL ANTICOAGULANTS (NOAC) THERAPY UNDERGOING UROLOGICAL SURGERY

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Modassar Awan ◽  
Eloise Merriott ◽  
Sybghat Rahim ◽  
Ibrahim Khawaja ◽  
Sam Datta ◽  
...  
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Urological Surgery

Guideline for stopping anticoagulants prior to urological procedures

2017 ◽  
Vol 11 (4) ◽  
pp. 271-279
Author(s):  
Abi Kanthabalan ◽  
Chris Dawson
Keyword(s):  
Antiplatelet Therapy ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Current Evidence ◽  
Local Hospital ◽  
Urological Procedures

There is a lack of clear evidence and guidelines on how to reverse anticoagulation prior to emergency and elective urological procedures. Our aim was to produce local hospital guidelines based on current evidence to simplify the perioperative process of stopping traditional and novel oral anticoagulants and antiplatelet therapy.

Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence

2019 ◽  
Vol 24 (38) ◽  
pp. 4511-4515 ◽  
Author(s):  
A. Koutsoumpelis ◽  
C. Argyriou ◽  
K.M. Tasopoulou ◽  
E.I. Georgakarakos ◽  
G.S. Georgiadis
Keyword(s):  
Peripheral Artery Disease ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Current Evidence ◽  
Peripheral Artery ◽  
Cardiac Events ◽  
Traditional Therapy ◽  
Cardiovascular Morbidity And Mortality ◽  
Increased Risk ◽  
Artery Disease

Background: Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality. In addition, the progression of peripheral artery disease leads to an increased risk of limb loss. In order to reduce these events, the benchmark of treatment and research over the last years has been the antiplatelet therapy which aims at inhibition of platelet aggregation. Over the last years, new studies combining antiplatelet agents in different therapeutic schemes have been proven efficacious. Unfortunately, patients remain still at high risk of CV events. Novel Oral Anticoagulants have been introduced as alternatives to warfarin, in the prevention and treatment of venous thromboembolism. The rationale of using medication which acts on platelet activation and the coagulation pathway of thrombosis has led investigators to examine the role of Noac's in preventing CV events in patients with peripheral artery disease, stable or unstable. Methods: The aim of this study is to review the current evidence with respect to recently published studies concerning the use of Novel anticoagulants in peripheral artery disease. Results: The Compass trial has shown that a combination of rivaroxaban with traditional therapy may produce promising results in reducing amputation rates, stroke, cardiac events, and mortality, however, there are still safety issues with bleeding requiring acute care. The ePAD study has provided us with insight concerning safety and efficacy after peripheral angioplasty or stenting and actually the need for further research. The Voyager Pad study, following the steps of Compass, is studying the effect and safety of the addition of rivaroxaban to traditional therapy in the highest risk population aka patients undergoing peripheral revascularization. The evidence concerning patients with concomitant atrial fibrillation appears to be insufficient, however, recent guidelines propose the use of novel oral anticoagulants. Conclusion: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most.

scholarly journals Checklists for the use of novel oral anticoagulants by the front-line clinician

2015 ◽  
Vol 148 (5) ◽  
pp. 241-245 ◽  
Author(s):  
Tammy J. Bungard ◽  
Jennifer Bolt ◽  
Peter Thomson ◽  
William Semchuk ◽  
Jennifer Lowerison
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Front Line

Novel oral anticoagulants: beyond the myth

2016 ◽  
Vol 33 (1) ◽  
pp. 125-127
Author(s):  
C. Setacci ◽  
M.P. Borrelli ◽  
M. Mele ◽  
G.F. Fadda
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants
Sign in / Sign up

Export Citation Format

Share Document